Checkmate Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference

About Checkmate Pharmaceuticals

Checkmate Pharmaceuticals is a clinical stage company that is leveraging its expertise in the field of CpG oligonucleotides to discover and develop immunotherapies designed to increase the efficacy of existing immunotherapies and to provide new treatment options for patients and their healthcare providers. Checkmate’s lead product candidate, CMP-001, is an investigational cancer immunotherapeutic that has been shown to reverse resistance to PD-1 therapy in some patients. Checkmate is a privately held company headquartered in Cambridge, MA. Additional information regarding Checkmate is available at www.checkmatepharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200108005113/en/